Pharma


  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners

    With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth. 

    By June 24, 2024
  • window woman
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 windows of opportunity in women’s health

    Despite a recent surge of interest, the femtech and women’s health markets are far from reaching their full potential.

    By Alexandra Pecci • June 21, 2024
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Historic main building of the National Institutes of Health
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    NIH-funded trials fall flat on diversity goals

    Many clinical trials aren’t meeting enrollment inclusion checkpoints — and some aren’t even setting targets, according to a recent OIG report.

    By June 20, 2024
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    New data showcase promise, growing pains of CAR-T in autoimmune disease

    One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

    By Ben Fidler • June 20, 2024
  • Junk yard
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

    Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.

    By June 18, 2024
  • Brain scans of a person with Alzheimer's are seen in this conceptual image.
    Image attribution tooltip
    digicomphoto via Getty Images
    Image attribution tooltip

    The hunt for the brain’s biomarkers

    How Roche is finding better ways to diagnose brain conditions like Alzheimer’s and Parkinson’s disease.

    By Kelly Bilodeau • June 17, 2024
  • Paxlovid
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll

    While researchers gain ground understanding long COVID’s impact, viable treatments could still be a long way off.

    By June 14, 2024
  • A 3D illustration showing amyloid plaques in brain tissue
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

    Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.

    By June 13, 2024
  • digital blue pill on computer chip background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the powerful computations, AI’s role in pharma is still beset by challenges

    Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.

    By June 12, 2024
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    As Big Pharma places bigger bets on ADCs, here’s where the field is headed next

    With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.

    By June 11, 2024
  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA’s platform designation aims to ease R&D pain points

    A new program creates approval pathways for multiple drugs developed on the same platform. 

    By June 11, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Behind Big Pharma’s layoffs — is there an end in sight?

    A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

    By Kelly Bilodeau • June 10, 2024
  • gambling chips
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s R&D gamble: picking pipeline winners in a risky field

    How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

    By June 7, 2024
  • City of Hope Helford Clinical Research Hospital in Duarte, California
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

    Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

    By June 6, 2024
  • brand name drugs
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    What’s in a drug name? More than you might think.

    From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.

    By Alexandra Pecci • June 4, 2024
  • Medicine capsules on blue racing lines
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In an era of big patent losses, drug launches need years of runway

    Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

    By June 3, 2024
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    After two Big Pharma deals, Nimbus looks to keep the hits coming

    With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.

    By Kelly Bilodeau • June 3, 2024
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

    Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

    By June 3, 2024
  • Dave Kappos, former director, U.S. PTO
    Image attribution tooltip
    Permission granted by Cravath, Swaine & Moore
    Image attribution tooltip

    As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’

    To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.

    By May 30, 2024
  • ftc federal trade commission
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    FTC request may signal trouble for Novo/Catalent deal

    As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.

    By Kelly Bilodeau • May 29, 2024
  • Abstract hand, falling can of pills, pills. Artwork or creative collage with art design
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As weight loss booms, drugmakers look for an edge with oral options

    Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.  

    By May 28, 2024
  • two syringes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where competition is heating up in pharma

    The stage is set for potential blockbuster-level showdowns targeting these three indications.

    By May 24, 2024
  • Pascal Soriot, CEO, AstraZeneca
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets

    Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

    By May 23, 2024
  • Online prescription DTC drugs
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field

    Companies like UpScriptHealth led the charge with online prescriptions decades ago, and now the industry is catching on to solve some of healthcare’s most pressing issues.

    By May 22, 2024
  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

    Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.  

    By May 22, 2024